Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 6, 2014, Pages 1081-1086

  Zhao, Defeng ^a   Qian, Liren ^a   Shen, Jianliang ^a   Liu, Xiaopeng ^a   Mei, Ke ^b   Cen, Jian ^a   Wang, Yaming ^a   Li, Congyong ^a   Ma, Yuanyuan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Diffuse large B cell lymphoma; Primary central nervous system lymphoma; R IDARAM; Stereotactic brachytherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DEXAMETHASONE; IDARUBICIN; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB;

CANCER STAGING; CASE REPORT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMAN; LYMPHOMA; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PROGNOSIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; CYTARABINE; DEXAMETHASONE; FEMALE; HUMANS; IDARUBICIN; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; PROGNOSIS;

EID: 84904745846     PISSN: 15821838     EISSN: 15824934     Source Type: Journal    
DOI: 10.1111/jcmm.12252     Document Type: Article

References (34)

1. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010; 67: 291-7.
2. Moreton P, Morgan GJ, Gilson D, et al. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemother Pharmacol. 2004; 53: 324-8.
3. Miller DC, Hochberg FH, Harris NL, et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer. 1994; 74: 1383-97.
4. Jahnke K, Thiel E, Schilling A, et al. Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol. 2005; 128: 616-24.
5. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994; 81: 188-95.
6. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998; 16: 859-63.
7. Ferreri AJ, Reni M, Dell'Oro S, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001; 60: 134-40.
8. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23: 5034-43.
9. Ruge MI, Kickingereder P, Grau S, et al. Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region. Neuro Oncol. 2013; 15: 1721-31.
10. Krema H, Heydarian M, Beiki-Ardakani A, et al. Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma. Int J Radiat Oncol Biol Phys. 2013; 86: 510-5.
11. Apuzzo ML, Petrovich Z, Luxton G, et al. Interstitial radiobrachytherapy of malignant cerebral neoplasms: rationale, methodology, prospects. Neurol Res. 1987; 9: 91-100.
12. Yu X, Liu Z, Tian Z, et al. Stereotactic biopsy for intracranial space-occupying lesions: clinical analysis of 550 cases. Stereotact Funct Neurosurg. 2000; 75: 103-8.
13. Yu X, Liu Z, Tian Z, et al. CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases. Chin Med. 1998; 111: 361-3.
14. Sun J, Zhang J, Yu X, et al. Stereotactic radiosurgery for trigeminal schwannoma: a clinical retrospective study in 52 cases. Stereotact Funct Neurosurg. 2013; 91: 236-42.
15. Yu X, Huang R, Qian W, et al. Stereotactic radiosurgery to treat presumed Rathke's cleft cysts. Br J Neurosurg. 2012; 26: 684-91.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-55.
17. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000; 36: 69-86.
18. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007; 25: 4730-5.
19. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003; 21: 4483-8.
20. Bessell EM, Graus F, Lopez-Guillermo A, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2001; 50: 457-64.
21. Yilmaz M, Erkutlu I, Kilciksiz S, et al. Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases. Hematology. 2008; 13: 107-13.
22. Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep. 1986; 70: 1059-65.
23. Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res. 1990; 50: 6525-8.
24. Walker MD, Hilton J. Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep. 1976; 60: 725-8.
25. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101: 466-8.
26. Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol. 2000; 20: 149-63.
27. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000; 18: 519-26.
28. Shibamoto Y, Ogino H, Hasegawa M, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005; 62: 809-13.
29. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002; 20: 4643-8.
30. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005; 19: 689-703.
31. Schwarz SB, Thon N, Nikolajek K, et al. Iodine-125 brachytherapy for brain tumours-a review. Radiat Oncol. 2012; 7: 30.
32. Ruge MI, Kickingereder P, Simon T, et al. Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. J Neurooncol. 2012; 109: 273-83.
33. Ruge MI, Simon T, Suchorska B, et al. Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. J Clin Oncol. 2011; 29: 4151-9.
34. Kreth FW, Thon N, Siefert A, et al. The place of interstitial brachytherapy and radiosurgery for low-grade gliomas. Adv Tech Stand Neurosurg. 2010; 35: 183-212.